Evidence map›Paper›PMID 34080108›Full record

ReviewJournal of general internal medicine2021

Who Will Be Responsible for the Dialysis Bill? A Case Report and Narrative Review of Insulin Affordability 100 Years After the Discovery of Insulin.

Alheli Arce Gastelum, Sima Maraqa, Walter Ariel Marquez Lavenant, Ammara Khan, Robert S McMahon, Azka Latif, Theresa A Townley

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of general internal medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Barriers to WHO prequalification of similar biotherapeutic insulin.Bulletin of the World Health Organization · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alheli Arce GastelumInternal Medicine Residency Program, Creighton University School of Medicine, Omaha, NE, USA. Aar46751@creighton.edu.ORCID http://orcid.org/0000-0001-7967-075X
Sima MaraqaInternal Medicine Residency Program, Creighton University School of Medicine, Omaha, NE, USA.
Walter Ariel Marquez LavenantCollege of Public Health, University of Nebraska Medical Center, Omaha, NE, USA.
Ammara KhanInternal Medicine Residency Program, Creighton University School of Medicine, Omaha, NE, USA.
Robert S McMahonCreighton University School of Medicine, Omaha, NE, USA.
Azka LatifInternal Medicine Residency Program, Creighton University School of Medicine, Omaha, NE, USA.
Theresa A TownleyInternal Medicine Department, Creighton University School of Medicine, Omaha, NE, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 46-year-old woman was type 1 diabetes diagnosed at the age of 9 who had previously been on an insulin pump. Other co-morbidities included CKD IV, HTN, and hypothyroidism. She presented with hyperglycemia of 400 mg/dl and fluid retention. Her GFR had decreased to 13. Her physical exam was notable for respiratory distress and anasarca. She failed to respond to aggressive IV diuresis and urgent hemodialysis was initiated. The patient had been lost to outpatient follow-up for a year. She had been co-managed by an endocrinologist and a primary care physician but had stopped going to her endocrinologist over a year ago due to inability to afford the co-pays. She subsequently lost her insurance and had to pay out of pocket for her insulin; at this point, she decided to stop seeing her PCP and began to ration her insulin. Due to social stigma, she did not mention her financial issues to her healthcare providers. After identifying these challenges, we decided to start her on a more affordable regimen of NPH insulin. Through social work assistance, we were able to obtain a charity hemodialysis chair and discharge her home. She applied to Medicaid. Healthcare expenditure with regard to diabetes rose to $327 billion from $245 billion in 2012. The price of insulin has continued to increase even after the drug's patent has expired due to the combination of FDA requirements, a monopoly in the insulin market, and the lack of federal price controls and Pharmacy Benefits Managers. The high out of pocket costs for insulin has led to many instances of insulin rationing among both uninsured and insured. This led to death in some cases as well as poorly controlled diabetes with increased complications and mortality as in our case. We present a case report and narrative review on insulin affordability.

Indexed as

chronic kidney diseasedialysisend-stage renal diseasehealthcare disparitiesinsulininsulin costnarrative reviewtype one diabetestype two diabetes

Identifiers

PMID34080108

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.